CY1120481T1 - Kv1.3 ανταγωνιστες και μεθοδοι χρησης - Google Patents

Kv1.3 ανταγωνιστες και μεθοδοι χρησης

Info

Publication number
CY1120481T1
CY1120481T1 CY20181100787T CY181100787T CY1120481T1 CY 1120481 T1 CY1120481 T1 CY 1120481T1 CY 20181100787 T CY20181100787 T CY 20181100787T CY 181100787 T CY181100787 T CY 181100787T CY 1120481 T1 CY1120481 T1 CY 1120481T1
Authority
CY
Cyprus
Prior art keywords
methods
competitors
antagonists
preparing
relates
Prior art date
Application number
CY20181100787T
Other languages
English (en)
Inventor
Ellen Chi
Wilson EDWARDS
Chichi Huang
Wai-Ping Leung
Ronald Swanson
Alan Wickenden
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of CY1120481T1 publication Critical patent/CY1120481T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

Η παρούσα εφεύρεση σχετίζεται με Κv1.3 ανταγωνιστές, και με πολυνουκλεοτίδια που τους κωδικεύουν, και με μεθόδους παρασκευής χρήσης των προηγουμένων.
CY20181100787T 2013-01-25 2018-07-31 Kv1.3 ανταγωνιστες και μεθοδοι χρησης CY1120481T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756777P 2013-01-25 2013-01-25
US201361757389P 2013-01-28 2013-01-28
PCT/US2014/012932 WO2014116937A1 (en) 2013-01-25 2014-01-24 Kv1.3 antagonists and methods of use

Publications (1)

Publication Number Publication Date
CY1120481T1 true CY1120481T1 (el) 2019-07-10

Family

ID=51228060

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100787T CY1120481T1 (el) 2013-01-25 2018-07-31 Kv1.3 ανταγωνιστες και μεθοδοι χρησης

Country Status (28)

Country Link
US (2) US10179808B2 (el)
EP (1) EP2948559B1 (el)
JP (1) JP6469590B2 (el)
KR (1) KR102268830B1 (el)
CN (1) CN104937105A (el)
AU (1) AU2014209227B2 (el)
BR (1) BR112015017795A2 (el)
CA (1) CA2898496A1 (el)
CY (1) CY1120481T1 (el)
DK (1) DK2948559T3 (el)
EA (1) EA037308B1 (el)
ES (1) ES2671434T3 (el)
HR (1) HRP20181055T1 (el)
HU (1) HUE039465T2 (el)
IL (1) IL239927B (el)
LT (1) LT2948559T (el)
MX (1) MX365987B (el)
NZ (1) NZ709913A (el)
PH (1) PH12015501627A1 (el)
PL (1) PL2948559T3 (el)
PT (1) PT2948559T (el)
RS (1) RS57422B1 (el)
SG (1) SG11201505508TA (el)
SI (1) SI2948559T1 (el)
TR (1) TR201809377T4 (el)
UA (1) UA117824C2 (el)
WO (1) WO2014116937A1 (el)
ZA (1) ZA201506131B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015303825B2 (en) * 2014-08-15 2021-01-14 Baylor College Of Medicine Novel potassium channel blockers and use thereof in the treatment of autoimmune diseases
CN107530887B (zh) 2015-03-05 2020-11-20 哈佛大学董事会 机器人抓握器、联动装置及用于机器人抓握的方法
CA3022961A1 (en) 2016-05-02 2017-11-09 Tetragenetics, Inc. Anti-kv1.3 antibodies, and methods of production and use thereof
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
TW201808987A (zh) 2016-06-08 2018-03-16 健生生物科技公司 Ｇｍ－ｃｓｆ變體及使用方法
CN106589092A (zh) * 2016-12-22 2017-04-26 中国科学技术大学先进技术研究院 一种蝎毒素多肽及制备拥有类似天然生理功能的蝎毒素多肽的方法
CN106957357B (zh) * 2017-04-01 2021-02-19 合肥科生景肽生物科技有限公司 一种蝎毒素多肽及其合成方法
EP4031162A1 (en) 2019-09-20 2022-07-27 Zealand Pharma A/S Kv1.3 blockers
IL305219A (en) 2021-03-23 2023-10-01 Zealand Pharma As Line suppressors 1.3 which have been changed
WO2024083919A1 (en) 2022-10-18 2024-04-25 Zealand Pharma A/S Inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
ES2340857T3 (es) 1997-09-16 2010-06-10 Centocor Ortho Biotech Inc. Metodo para la sintesis quimica completa y emsamblaje de genes y genomas.
GB0414272D0 (en) * 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
JP5118969B2 (ja) 2004-10-07 2013-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア Ｋｖ１．３カリウムチャネルの選択的阻害におけるＳｈＫトキシンの類似体ならびにその使用方法
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US8043829B2 (en) 2006-10-25 2011-10-25 Amgen Inc. DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
EP2738257A1 (en) * 2007-05-22 2014-06-04 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
EP2229473A4 (en) * 2007-12-07 2011-02-02 Steven A Goldstein IDENTIFICATION OF TOXIN LIGANDS
WO2010017632A1 (en) * 2008-08-13 2010-02-18 The University Of British Columbia Methods for stimulating chondrogenesis utilizing a potassium channel inhibitor
JP2012521360A (ja) * 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｋｖ１．３の選択的かつ強力なペプチド阻害剤
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Also Published As

Publication number Publication date
CA2898496A1 (en) 2014-07-31
HUE039465T2 (hu) 2019-01-28
KR20150108912A (ko) 2015-09-30
JP6469590B2 (ja) 2019-02-13
PT2948559T (pt) 2018-07-24
EA037308B1 (ru) 2021-03-10
US20140255401A1 (en) 2014-09-11
HRP20181055T1 (hr) 2018-09-07
BR112015017795A2 (pt) 2017-11-21
WO2014116937A1 (en) 2014-07-31
NZ709913A (en) 2019-05-31
DK2948559T3 (en) 2018-05-28
EP2948559A1 (en) 2015-12-02
EP2948559B1 (en) 2018-05-02
MX365987B (es) 2019-06-20
PH12015501627B1 (en) 2015-09-21
IL239927A0 (en) 2015-08-31
LT2948559T (lt) 2018-06-25
TR201809377T4 (tr) 2018-07-23
AU2014209227B2 (en) 2017-11-23
ZA201506131B (en) 2017-06-28
PH12015501627A1 (en) 2015-09-21
EA201591380A1 (ru) 2015-12-30
CN104937105A (zh) 2015-09-23
JP2016505639A (ja) 2016-02-25
SI2948559T1 (en) 2018-08-31
SG11201505508TA (en) 2015-08-28
IL239927B (en) 2020-10-29
EP2948559A4 (en) 2016-10-19
UA117824C2 (uk) 2018-10-10
AU2014209227A1 (en) 2015-07-30
RS57422B1 (sr) 2018-09-28
US20190062383A1 (en) 2019-02-28
ES2671434T3 (es) 2018-06-06
MX2015009632A (es) 2015-11-30
PL2948559T3 (pl) 2018-09-28
KR102268830B1 (ko) 2021-06-24
US10179808B2 (en) 2019-01-15

Similar Documents

Publication Publication Date Title
CY1122308T1 (el) St2l ανταγωνιστες και μεθοδοι χρησης
CY1120481T1 (el) Kv1.3 ανταγωνιστες και μεθοδοι χρησης
CY1124004T1 (el) Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους
CY1124740T1 (el) Συνθεσεις που περιλαμβανουν συνθετiκα πολυνουκλεοτιδια που κωδικοποιουν crispr σχετικες πρωτεϊνες και συνθετικα sgrnas και μεθοδοι χρησης
CY1121750T1 (el) Cot διαμορφωτες και μεθοδοι χρησης αυτων
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
CY1121891T1 (el) Τροποποιημενα με γενετικη μηχανικη πολυπεπτιδια της λυασης φαινυλαλανινης-αμμωνιας
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
DK3587417T3 (da) 1,3-thiazol-2-yl-substituerede benzamider
EA201591137A1 (ru) Ингибиторы mk2 и их применения
BR112015019647A2 (pt) criação de perfil de caminho com uso de combinação de hardware e software.
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
BR112017018834A2 (pt) variantes de protoxina-ii e métodos de uso
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
PH12016500598A1 (en) Protoxin-ii variants and methods of use
BR112017020896A2 (pt) variantes de protoxina-ii e métodos de uso
CY1124445T1 (el) Αντισωματα αντι-ccl17
CL2015002358A1 (es) Compuestos bicíclicos.
CY1121749T1 (el) Προφαρμακα ανταγωνιστων nmda
ITUA20162350A1 (it) Composizione per decolorare la fibra cheratinica
CY1119212T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
EA201691049A1 (ru) Энтомотоксичные полипептиды
TR201303038A2 (tr) Bir krem.
TH1601002801A (th) วิธีผลิต 2, 3-บิวเทนไดออล